We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Early Feasibility Study of the Orion Visual Cortical Prosthesis System

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03344848
Recruitment Status : Active, not recruiting
First Posted : November 17, 2017
Last Update Posted : January 12, 2023
National Institute of Neurological Disorders and Stroke (NINDS)
Information provided by (Responsible Party):
Second Sight Medical Products

Brief Summary:
This is an early feasibility study of a new device, the Orion Visual Cortical Prosthesis System. The device is intended to stimulate the surface of the visual cortex to induce visual perception in blind individuals.

Condition or disease Intervention/treatment Phase
Blindness, Acquired Device: Orion Visual Cortical Prosthesis System Not Applicable

Detailed Description:
In this study, 6 subjects with bare light or no light perception in both eyes will be implanted with the Orion Cortical Visual Prosthesis System. The study will evaluate the safety of the device and surgery, as well as reliability of the system and the usefulness of any restored vision. Each subject will be followed for 5 years, with their health monitored throughout. Research sessions, visual function testing, and subject-reported outcomes will be used to evaluate the functioning of the system.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 6 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Device Feasibility
Official Title: Early Feasibility Study of the Orion Visual Cortical Prosthesis System
Actual Study Start Date : November 20, 2017
Estimated Primary Completion Date : June 1, 2023
Estimated Study Completion Date : March 1, 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Artificial Limbs

Arm Intervention/treatment
Experimental: Single Arm
Implanted with the Orion Visual Cortical Prosthesis System
Device: Orion Visual Cortical Prosthesis System
The Orion Visual Cortical Prosthesis System is intended to stimulate the medial surface of the occipital lobe in the visual cortex to induce visual perception in blind individuals.

Primary Outcome Measures :
  1. Rate of Device- or Procedure-Related Adverse Events (Safety) [ Time Frame: Through study completion, an average of 5 years ]
    Collection of adverse events

Secondary Outcome Measures :
  1. Ability to Create Visual Perception as Measured by Stimulation Thresholds [ Time Frame: 1 month, 6 months, 12 months, 24 months, 60 months ]
    Measurement of stimulation thresholds on each electrode or groups of electrodes

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   22 Years to 74 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Subject is bilaterally blind with bare or no light perception. This is defined as non-measurable binocular visual acuity or 5° or less visual field in each eye.
  2. Subject is bilaterally blind due to:

    1. Trauma to the eye, or
    2. Disease or damage of the retina (such as retinopathy, retinal vein occlusion, inherited retinal diseases or retinal detachment), or
    3. Disease or damage of the optic nerve or chiasm (such as glaucoma, methanol intoxication, autoimmune neuropathies, pituitary pathology, and hereditary neuropathies)
  3. Subject's vision cannot be restored with any approved medication or intervention.
  4. Subject has a documented history of useful form vision.
  5. Subject is between the age of 22-74 .
  6. Subject resides within 2 hours (by ground transportation) of the investigational site.
  7. Subject is (a) male or (b) a female of childbearing potential with a negative pregnancy test who is using a reliable method of contraception or (c) a female who is at least two years post-menopause or otherwise unable to bear children.
  8. Subject is able to complete regular office and telephone appointments per the protocol requirements.
  9. Subject is medically fit for neurosurgical intervention.

Exclusion Criteria:

  1. Subject is at high risk for surgical complications such as active systemic infection, coagulation disorders (such as the use of anti-thrombotic therapies) or platelet count below 100,000.
  2. Subject has history of bleeding or immune compromise.
  3. Subject is taking chronic anticoagulants or antiplatelet agent or subject has an abnormally elevated preoperative coagulation profile (either PTT or PT/INR).
  4. Subject has had prior craniotomy or brain surgery that would interfere with placement or function of Orion device.
  5. Subject has evidence of active intracranial disease that would preclude elective neurosurgical intervention, such as unruptured intracranial aneurysm or brain tumor, or aberrant visual cortex anatomy, such as prior stroke or arteriovenous malformation.
  6. Subject has a significant abnormality on preoperative brain MRI.
  7. Subject has a prior history of seizures or epilepsy.
  8. Subject has Parkinson's disease.
  9. Subject has a prior history of serious head injury with loss of consciousness for more than 24 hours.
  10. Subject has a progressive central nervous system disease.
  11. Subject has a history of implant-related infection.
  12. Subject requires or is likely to require any of the following medical procedures while implanted with the Orion System: MR imaging, diathermy, electroconvulsive therapy (ECT), or transcranial magnetic stimulation (TMS). These medical procedures are contraindicated for subjects implanted with an Orion System. Energy from these procedures can be sent through the implanted brain stimulation system and cause permanent brain damage which may cause severe injury, coma, or death.
  13. Subject is implanted with any neurostimulation or neuromodulation device in the head including, but not limited to cochlear implant, deep brain stimulator, or auditory brain implant.
  14. Subject has a clinically significant or unstable medical condition including uncontrolled systemic hypertension with values above 170/100; cardiac or pulmonary disease; uncorrected coagulation abnormalities; diabetes; or any condition that would render the patient unable to safely cooperate with the study tests as judged by the screening physician.
  15. Subject has had an alcohol or illicit substance use disorder within the last 6 months, unstable remission of substance abuse, or chart evidence that co-morbid substance use disorder could account for lack of treatment response.
  16. Subject has uncontrolled chronic pain.
  17. Subject has significant neurocognitive impairment in memory domain (based on MoCA-BLIND <18 or WAIS-IV <80, described below).
  18. Subject had moderate or severe depression, as determined by a score of at least 17 on the HAM-D.
  19. Subject has had a suicide attempt in the last two years, presence of a suicide plan (an answer of "Yes" to Question C4 in Section C-Suicidality of MINI International Neuropsychiatric Interview), or a "yes" answer to any one of the ten suicidal ideation and behavior questions on the C-SSRS.
  20. Subject has a disease or condition that prevents understanding or communication of informed consent, study demands, or testing protocols, including:

    1. Cognitive decline including diagnosed forms of dementia and/or progressive neurologic disease
    2. Psychiatric disease including diagnosed forms of depression
    3. Does not speak a principal language associated with the region
    4. Deafness or selective frequency hearing loss that prevents adequate communication with the researchers.
  21. Subject has a balance disability or frequently participates in contact sports.
  22. Subject must administer diathermy as part of his/her livelihood.
  23. Subject is pregnant or is planning on becoming pregnant in the next year.
  24. Subject has unrealistic expectations of the benefits of the study.
  25. Subject is enrolled in another therapeutic investigational drug or device trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03344848

Layout table for location information
United States, California
University of California, Los Angeles
Los Angeles, California, United States, 90025
United States, Texas
Baylor College of Medicine
Houston, Texas, United States, 77030
Sponsors and Collaborators
Second Sight Medical Products
National Institute of Neurological Disorders and Stroke (NINDS)
Layout table for investigator information
Study Director: Uday Patel, PhD Second Sight Medical Products
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Second Sight Medical Products
ClinicalTrials.gov Identifier: NCT03344848    
Other Study ID Numbers: CP-07
5UH3NS103442 ( U.S. NIH Grant/Contract )
First Posted: November 17, 2017    Key Record Dates
Last Update Posted: January 12, 2023
Last Verified: January 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Vision Disorders
Sensation Disorders
Neurologic Manifestations
Nervous System Diseases
Eye Diseases